Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2018-03-16 AGM Information
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Korekta raportu bieżącego nr 7/2018 z dnia 13 marca 2018 roku w zakresie projektów uchwał na Nadzwyczajne Walne Zgromadzenie Celon Pharma S.A. zwołane na dzień 9 kwietnia 2018 roku - Content (PL)
AGM Information Classification · 95% confidence The document is a notification from the Management Board of Celon Pharma S.A. regarding corrections to draft resolutions intended for an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie or NWZ) scheduled for April 9, 2018. Specifically, it corrects an omission (missing resolution for the Scrutiny Committee) and an error in the proposed agenda for the NWZ. Since the document is correcting materials related to a shareholder meeting (NWZ) and its resolutions, it directly relates to the governance and proceedings of that meeting. The most fitting category is AGM Information (AGM-R), as NWZ is a type of General Meeting, and this document concerns the materials/resolutions for it. Although it is a correction, the core subject matter aligns best with AGM-R rather than a general Regulatory Filing (RNS) or a specific Voting Declaration (DVA), as it precedes the actual vote.
2018-03-16 Polish
Projekty Uchwał
AGM Information Classification · 99% confidence The document text is titled 'PROJEKTY UCHWAŁ NA NADZWYCZAJNE WALNE ZGROMADZENIE' (Draft Resolutions for the Extraordinary General Meeting) and contains specific resolutions ('Uchwała nr ...') regarding the election of the Chairman, adoption of the agenda, and appointment of a Supervisory Board member for an Extraordinary General Meeting (EGM). This content directly relates to the formal proceedings and materials presented or voted upon during a General Meeting. The closest matching category is 'AGM Information' (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although this is an EGM (Nadzwyczajne Walne Zgromadzenie), AGM-R is the designated code for General Meeting materials in the provided schema, distinguishing it from other specific filings like Director's Dealing or Earnings Releases.
2018-03-13 Polish
Ogłoszenie o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Celon Pharma S.A. na dzień 9 kwietnia 2018 roku wraz z projektami uchwał. - Content (PL)
AGM Information Classification · 100% confidence The document text is a formal announcement in Polish, starting with 'Zarząd Celon Pharma S.A. ... zwołuje na dzień 9 kwietnia 2018 roku, na godzinę 10:00, Nadzwyczajne Walne Zgromadzenie ("Walne Zgromadzenie")'. This explicitly states the convening of an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). The content details the proposed agenda (Proponowany porządek obrad), registration day (Dzień rejestracji), shareholder rights regarding participation and submitting proposals, and communication procedures. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM) or related preparatory notices. The appropriate code is AGM-R (AGM Information).
2018-03-13 Polish
Zakończenie II części badania klinicznego I fazy nad lekiem opartym na Esketaminie - Content (PL)
Regulatory Filings Classification · 92% confidence The document text is very short (1210 characters) and discusses the progress of a clinical trial for a drug based on Esketamine, referencing previous current reports (raport bieżący). It provides an update on the completion of Phase I, Part II of the clinical trial and outlines plans for Part III. This type of specific, ongoing operational update, especially concerning clinical trials or regulatory milestones, often falls under general regulatory announcements or specific operational updates. Since there is no specific category for 'Clinical Trial Update' and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), it fits best as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update (LTR) if the trial itself is considered a regulatory process. Given the context of reporting ongoing operational milestones that are material to the company's future, RNS (Regulatory Filings) is the most appropriate general category for non-standard, material announcements in Polish reporting context, especially when it doesn't fit the other specific financial/governance codes.
2018-03-07 Polish
Realizacja etapu II.1 prac związanych z syntezą substancji czynnej GLG-805 w ramach Projektu TNBC. - Content (PL)
Regulatory Filings Classification · 89% confidence The document is a short announcement (1519 characters) from the Management Board of GLG Pharma S.A. (Zarząd GLG Pharma S.A.) regarding the acceptance of a partial report (raport częściowy) for stage II.1 of work related to an agreement (Umowa) concerning the synthesis of substance GLG-805 for TNBC therapy development. It details the completion of specific research tasks (synthesis, validation, stress tests) and mentions that the next stage (II.2) can now commence. Since this is an announcement about the completion and acceptance of a specific research/development phase report, and not the full financial report (10-K, IR) or a general regulatory filing (RNS), it best fits the category for updates on specific projects or activities that aren't standard financial disclosures. Given the context of development work acceptance, it is most closely related to ongoing project updates. However, none of the definitions perfectly capture a 'Research Progress Report Acceptance'. Comparing the options: It is not a standard financial report (10-K, IR), not a management change (MANG), not a dividend (DIV), and not a general regulatory filing (RNS) as it is highly specific. It describes progress in a development project. Since it is a specific update on a project/agreement status, and not a general financial release, the closest fit among the provided specific codes is difficult. Given the content focuses on the progress of a specific contract/project, and it is an official communication, if it were a general regulatory filing that didn't fit elsewhere, RNS would be used. However, since it details the acceptance of a specific stage of work under a contract, and the text explicitly states that further stages will be reported in separate current reports, this functions as a specific operational update. In the absence of a 'Research Update' code, and noting it is a specific, non-financial, non-governance update, RNS (Regulatory Filings - fallback) is the most appropriate general category for specific, non-standard operational disclosures, although 'LTR' (Legal Proceedings Report) is incorrect, and 'CAP' (Financing) is incorrect. Given the highly specific nature of the progress update, and the lack of a better fit, RNS is the safest fallback for a specific operational/project milestone announcement that isn't covered by the other detailed codes.
2018-02-20 Polish
Realizacja etapu IIa prac związanych z badaniami klinicznymi w ramach Projektu TNBC. - Content (PL)
Regulatory Filings Classification · 92% confidence The document is a formal announcement by the Management Board (Zarząd) of GLG Pharma S.A. regarding the acceptance of a partial report from a contractor (IQ Pharma S.A.) concerning work done under a specific agreement (Umowa) related to clinical trials for a product (GLG-801). It details regulatory submissions (to URPL and Bioethics Committee) and outlines the next steps. This type of communication, detailing specific operational progress, regulatory milestones, and contractual updates, is characteristic of ongoing business and operational disclosures. Since it is not a full annual report (10-K), a formal earnings release (ER), or a dividend notice (DIV), and it specifically discusses legal/regulatory progress related to product development and contractual obligations, it fits best under the general category of Regulatory Filings (RNS) as a specific operational update that doesn't match the other specialized codes. Given the short length and the nature of reporting on a specific operational/regulatory step, RNS is the most appropriate fallback, although it contains elements of LTR (Legal Proceedings Report) due to regulatory interaction, RNS covers general regulatory announcements well.
2018-02-19 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.